Key result
Musculin mirrors MyoD genomic binding in rhabdomyosarcoma cells, suggesting a broad role buffering MyoD activity.
Why the study?
The genome-wide binding pattern of the myogenic inhibitor musculin relative to the widespread binding of MyoD in rhabdomyosarcoma cells was unknown.
The myogenic inhibitor MSC binds throughout the genome in a pattern highly similar to MyoD, suggesting a broad role in buffering MyoD activity in development and rhabdomyosarcomas.
MSC binds genome-wide similarly to MyoD in RMS cells; leaves open buffering role in myogenic differentiation and therapeutic targeting.
BACKGROUND: Musculin (MSC) is a basic helix-loop-helix transcription factor that inhibits myogenesis during normal development and contributes to the differentiation defect in rhabdomyosarcoma. As one of many transcription factors that impede myogenesis, its binding on a genome-wide scale relative to the widespread binding of the myogenic factor MyoD is unknown. METHODS: Chromatin immunoprecipitation coupled to high-throughput sequencing was performed for endogenous MSC in rhabdomyosarcoma cells and its binding was compared to that of MyoD in the same type of cells. RESULTS: MSC binds throughout the genome, in a pattern very similar to MyoD. Its binding overlaps strongly with regions enriched for acetylated histone H4, as well as regions that score high for DNase hypersensitivity in human myoblasts. In contrast to MyoD, MSC has a more relaxed binding sequence preference in the nucleotides that flank the core E-box motif. CONCLUSIONS: The myogenic inhibitor MSC binds throughout the genome of rhabdomyosarcoma cells, in a pattern highly similar to that of MyoD, suggesting a broad role in buffering the activity of MyoD in development and rhabdomyosarcomas.
No takes yet. Share an insight, caveat, or question.
MacQuarrie et al. (2013) studied Rhabdomyosarcoma. Musculin (MSC) binding vs. MyoD binding was evaluated on Genome-wide binding locations of MSC compared to MyoD. Musculin binds widely throughout the genome of rhabdomyosarcoma cells in a pattern highly similar to MyoD, suggesting a broad role in buffering MyoD activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: